Id |
Subject |
Object |
Predicate |
Lexical cue |
T3 |
0-126 |
Sentence |
denotes |
Severe acute respiratory syndrome virus 2 (SARS-CoV-2) is the cause of the current coronavirus disease 19 (COVID-19) pandemic. |
T4 |
127-282 |
Sentence |
denotes |
Protease inhibitors are under consideration as virus entry inhibitors that prevent the cleavage of the coronavirus spike (S) protein by cellular proteases. |
T5 |
283-479 |
Sentence |
denotes |
Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations. |
T6 |
480-634 |
Sentence |
denotes |
An analysis of proteomics and translatome data indicated that SARS-CoV-2 replication is associated with a downregulation of host cell protease inhibitors. |
T7 |
635-743 |
Sentence |
denotes |
Hence, aprotinin may compensate for downregulated host cell proteases during later virus replication cycles. |
T8 |
744-930 |
Sentence |
denotes |
Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air–liquid interface cultures) and against four virus isolates. |
T9 |
931-1014 |
Sentence |
denotes |
In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity. |
T10 |
1015-1191 |
Sentence |
denotes |
An approved aprotinin aerosol may have potential for the early local control of SARS-CoV-2 replication and the prevention of COVID-19 progression to a severe, systemic disease. |